Brind.

Metsera Inc benefited from Trump-era tariffs and saw Bank of America raise its price target following clinical data announcements.

1 report, 1 independent Updated Aug 20

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Metsera Inc Bank of America Donald Trump

Keep exploring

The entities involved

Metsera Inc
biotechnology company

Nothing else this week.
Bank of America
American multinational banking and financial services corporation
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
- Both Bank of America and Deloitte have addressed current treasury management trends.Mon 14:26
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Trump ended the ceasefire agreement with Iran following recent attacks by Iranian forces.Mon 18:02
- The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02

Related events

Coverage

Newest first; wire copies grouped

Aug 20Insider MonkeyMetsera’s (MTSR) Amylin Agonist Data Leads to Price Target Increase Metsera Inc. (NASDAQ:MTSR) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 20, BofA raised